NZ334948A - Anthranilic acid derivatives as p-glycoprotein inhibitors useful for the treatment of multi drug-resistant cancers - Google Patents
Anthranilic acid derivatives as p-glycoprotein inhibitors useful for the treatment of multi drug-resistant cancersInfo
- Publication number
- NZ334948A NZ334948A NZ334948A NZ33494897A NZ334948A NZ 334948 A NZ334948 A NZ 334948A NZ 334948 A NZ334948 A NZ 334948A NZ 33494897 A NZ33494897 A NZ 33494897A NZ 334948 A NZ334948 A NZ 334948A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- ring
- halogen
- alkoxy
- r1or11
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
An anthranilic acid derivative of formula (I), wherein: each of R, R1 and R2, which are the same or different, is H, C1-C6 alkyl, OH, C1-C6 alkoxy, halogen, nitro, or, N(R1OR11) wherein each of R1O and R11, which are the same or different, is H or C1-C6 alkyl, or R1 and R2, being attached to adjacent positions of ring b, together form a methylenedioxy or ethylenedioxy group; R3 is H or C1-C6 alkyl; R4 is C1-C6 alkyl or R4 represents -CH2- or -CH2CH2- which is attached either (i) to position 2 of ring b to complete a saturated 5- or 6-membered nitrogen-containing ring fused to ring b or (ii) to the position in ring a adjacent to that to which X, being a single bond, is linked, thereby completing a saturated 5- or 6-membered nitrogen-containing ring fused to ring a; R5 is H, OH or C1-C6 alkyl; X is a direct bond, 0, S, -S-(CH2)p- or -0-(CH2)p- wherein p is an integer of 1 to 6; R6 is H, C1-C6 alkyl or C1-C6 alkoxy; q is 0 or 1; Ar is an unsaturated carbocyclic or heterocyclic group selected from furan, thiophene, pyrrole, indole, isoindole, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, pyridine, quinoline, quinoxaline, isoquinoline, thienopyrazine, pyran, pyrimidine, pyridazine, pyrazine, purine and triazine which is unsubstituted or substituted by one or more substituents selected from OH, halogen, C1-C6 alkyl, which is unsubstituted or substituted by halogen, C1-C6 alkoxy, nitro and N(R1OR11); each of R7 and R8, which are the same or different, is H, C1-C6 alkyl which is unsubstituted or substituted by one or more halogen atoms, C1-C6 alkoxy, hydroxy, halogen, phenyl, NHOH, nitro, N(R1OR11), or SR12 wherein R12 is H or C1-C6 alkyl; or R7 and R8, when situated on adjacent carbon atoms, form together with the carbon atoms to which they are attached a benzene ring or a methylenedioxy substituent; R9 is phenyl or an unsaturated heterocyclic group selected from furan, thiophene, pyrrole, indole, isoindole, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, pyridine, quinoline, quinoxaline, isoquinoline, thienopyrazine, pyran, pyrimidine, pyridazine, pyrazine, purine and triazine, each of which is unsubstituted or substituted by C1-C6 alkyl, OH, C1-C alkoxy, halogen, C3-C6 cycloalkyl, phenyl, benzyl, trifluoromethyl, nitro, acetyl, benzoyl or N(R1OR11), or two substituents on adjacent ring positions of the phenyl or heterocyclic group together complete a saturated or unsaturated 6-membered ring or form a methylenedioxy group; n is 0 or 1; and m is 0 or an integer of 1 to 6; Also disclosed are pharmaceutical compositions containing the above compound that can be used as an inhibitor of p-glycoprotein. The compound is useful as a modulator for multidrug resistance, for potentiating the cytotoxicity of a chemotherapeutic agent or enhancing the net absorption, distribution, metabolism or elimination characteristics of a therapeutic agent
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9602552 | 1996-10-18 | ||
GBGB9717576.4A GB9717576D0 (en) | 1997-08-19 | 1997-08-19 | Pharmaceutical compounds |
PCT/GB1997/002885 WO1998017648A1 (en) | 1996-10-18 | 1997-10-17 | Anthranilic acid derivatives as multi drug resistance modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ334948A true NZ334948A (en) | 2000-11-24 |
Family
ID=26308635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ334948A NZ334948A (en) | 1996-10-18 | 1997-10-17 | Anthranilic acid derivatives as p-glycoprotein inhibitors useful for the treatment of multi drug-resistant cancers |
Country Status (5)
Country | Link |
---|---|
MY (1) | MY118642A (en) |
NZ (1) | NZ334948A (en) |
RU (1) | RU2195454C2 (en) |
SK (1) | SK284649B6 (en) |
UA (1) | UA67730C2 (en) |
-
1997
- 1997-10-16 MY MYPI97004871A patent/MY118642A/en unknown
- 1997-10-17 SK SK509-99A patent/SK284649B6/en not_active IP Right Cessation
- 1997-10-17 RU RU99109990/04A patent/RU2195454C2/en not_active IP Right Cessation
- 1997-10-17 UA UA99042118A patent/UA67730C2/en unknown
- 1997-10-17 NZ NZ334948A patent/NZ334948A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SK284649B6 (en) | 2005-08-04 |
MY118642A (en) | 2004-12-31 |
UA67730C2 (en) | 2004-07-15 |
SK50999A3 (en) | 2000-08-14 |
RU2195454C2 (en) | 2002-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS49921B (en) | Therapeutic biaryl derivatives | |
YU11299A (en) | Indasole derivatives | |
MY132499A (en) | Substituted indazole derivatives and related compounds | |
YU60198A (en) | Substituted indazole derivatives and their use as phosphodiesteraze (pde) type iv and tumor necrosis factor (tnf) inhibitors | |
TW375609B (en) | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | |
DK1045830T3 (en) | Alpha-aminoamide derivatives useful as analgesic agents | |
AR032453A1 (en) | DERIVADOS ALQUINIL FENIL HETEROAROMATICOS ACTIVADORES DE GLUCOQUINASA, A PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS, THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF MEDICINES | |
DK34793A (en) | WATER SOLUBLE, PHARMACEUTICAL ACCEPTABLE SALT OF A MONOACYL DERIVATIVE OF RAPAMYCINE, PROCEDURE FOR ITS PREPARATION AND INJECTABLE, PHARMACEUTICAL PREPARATION CONTAINING IT | |
ES420211A1 (en) | Certain 4-amino-6-aryl-pyrimidines | |
CA2119662A1 (en) | New nitrogen bicyclic derivatives, their preparation process and pharmaceutical compositions comtaining them | |
HRP20031091B1 (en) | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | |
NZ334948A (en) | Anthranilic acid derivatives as p-glycoprotein inhibitors useful for the treatment of multi drug-resistant cancers | |
DE69718968D1 (en) | 3- (BIS-SUBSTITUTED-phenylmethylene) oxindole DERIVATIVES | |
GB1076089A (en) | New derivatives of imidazo [1,2-a]-pyridine and a process for the manufacture thereof | |
NZ309499A (en) | Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation | |
EA200400770A1 (en) | DERIVATIVES 5- (PIRIDIN-3-IL) -1-AZABICYCLO [3.2.1] OKTANA, THEIR RECEIVING AND APPLICATION IN THERAPY | |
AU526978B2 (en) | Tetracyclic indole derivatives | |
AU539177B2 (en) | Amino alkoxy pyrazoles | |
NZ228369A (en) | Heterocyclic substituted 5,7-dihydropyrrolo(3,2-f)-benzoxazol-6-ones, preparation and compositions thereof | |
AU3140300A (en) | Methods and compositions for treating leukemia | |
FR2694557B1 (en) | Tetrahydronaphthalene derivatives, their preparation, and their therapeutic application. | |
TW366344B (en) | Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives and pharmaceutical composition using the same | |
ES543784A0 (en) | PROCEDURE FOR THE PREPARATION OF A DERIVATIVE 1,1-DIFENILPRO- PAN-1-OL | |
FR2322601A1 (en) | Pyrrolidinone deriirrivs as tranquillizers - 1-Heterocyclyl-5(1-piperazinyl-carbonyloxy)-2(5H)-pyrrolidinone derivs prepd. from 5-aryloxycarbonyloxy cpds. and piperazine (OE060576) | |
FR2322600A1 (en) | Pyrrolidinone deriirrivs as tranquillizers - 1-Heterocyclyl-5(1-piperazinyl-carbonyloxy)-2(5H)-pyrrolidinone derivs prepd. from 5-aryloxycarbonyloxy cpds. and piperazine (OE060576) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |